Researchers working with StemSynergy Therapeutics discovered a class of WNT inhibitors that block colorectal cancer growth with minimal gastrointestinal toxicity.
Here's what you should know:
1. Researchers discovered CK1alpha agonists. CRC cells have low levels of CK1alpha. In preclinical studies, the agonists have shown "profound efficacy without the associated toxicity."
2. Other treatments that block the WNT pathway often exhibited "significant" gastrointestinal toxicity issues.
3. StemSynergy's Director of Medicinal Chemistry Darren Orton, MD, said in a release, "We are extremely pleased with the results of this study."
4. StemSyngery said the company plans to start phase I clinical trials within a year.